Excellence in Nanoparticle Analysis

Nanolyze develops patented solutions for helping researchers finding therapies for previously untreatable diseases. We want to unleash the full potential and push the frontiers in nanomedicine by providing researchers with easy-to-use and efficient tools, allowing label free real-time analysis of nanoparticles at single particle resolution.

OUR VALUES

Satisfaction, Transparency, and Excellence are our guiding stars, and we are Entrepreneurial and Purpose Driven.

THE COMPANY

Nanolyze is a deep-tech startup founded in 2020 with the ambition to become the leading company in the emerging field of instruments for analysis of particles in nanoscience. We are a strong team covering business development, engineering, and science, and we are strategically located at the AstraZeneca BioVentureHub in Gothenburg.

INVESTMENT CASE

We are currently looking for investments to enable market expansion by closing active leads, high frequency prospecting, and conference exposure. Get in contact here if you don't want to miss this golden opportunity when nanomedicine is emerging and the need for disruptive analytical tools is urgent.

External heroes and courageous early adopters

Prof Fredrik Höök, prominent researcher and entrepreneur in the field of bio-sensors, is an active founder of Nanolyze

“Nanolyze opens up unique opportunities to, for example, investigate how viruses, exosomes and drug delivery vehicles interact with proteins and biomolecules in different biological fluids (so called protein corona formation), how their stability varies in different storage conditions, as well as the kinetics of specific biomolecular binding reactions, which is of relevance in many diagnostic applications.”

Prof Samir El Andaluossi, Karolinska Institute, invested in Nanolyze Explore 2022

“The Nanolyze team has a clear user focus and Nanolyze Vision will have the potential to become a very powerful instrument with the power to move the boundaries of current state-of-the -art in the nanoparticle analysis field.”

Prof Tapani Viitula, Åbo Akademi University, invested in Nanolyze Explore 2023

“I have followed the development of the Nanolyze waveguide-based technology for analyzing nanoparticles with great interest. My main focus is drug and nanoparticle action and delivery, and I have great hopes to being able to push the boundaries of our research thanks to the unique capabilities that Nanolyze can offer.”